#1*SNDY.FACTS.Dates.Timeline - what you need to know*****
Stage 1 audit: 2/26/13 :completed
Stage 2 audit: 8/16/13
--//--
Important dates to watch
Quarterly financials
filing date 8/15/13
TUV 13485:2013 & CE mark
2-8 weeks after successful completion of stage 2 audit on 8/16/13
--//--
SNDY starting in 2008 timeline
2008 - 2009
Solos Endoscopy, Inc. Implements Strategy to Capitalize on $30 Billion Minimally Invasive Surgical Product Market.
Capital Change=shs decreased by 1 for 5000
SNDY medical devices become popular in hospitals, universities and health centers.
Appears in numerous medical magazines.
Gets FDA approval
Continues design with significant success
Sales increase
-
2010
Retains Expert resource to meet requirements for ISO 13485 quality management system initiative. Starts to develop European Union Conforming CE mark Technical files.
Granted U.S. Trademark for Mammoview(r).
Completes phase 1 requirements for ISO 13485
Appoints CFO Mr. Schiemann
Appears in more magazines.
product design continues.
Shareholder meeting:
Last R/S
BOSTON, Nov. 19, 2010 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company's management has approved its 2011 recapitalization plan in order to position itself for growth over the next twelve months. The recapitalization plan is designed to increase financial flexibility for Solos and its shareholders.
The recapitalization plan allows Solos greater flexibility to utilize the assets of the Company in the future for corporate purposes; including raising capital, acquisitions or employee compensation, with limited dilution of existing stockholder voting rights.
"We are very pleased that the recapitalization allows us to pursue our existing strategy more aggressively," stated Bob Segersten, President of Solos Endoscopy, Inc.
Throughout the remainder of 2010, the Company will continue its new product development for the MammoView product line.
-
2011
Revenue increases
Design and development continues
Decreases net loss by $1 million.
Introduces new urology instrument line
New website
Enters Veterinary market
Sales increase
SNDY donates portion of sales to the National Breast Cancer Foundation.
2012
Bariatric instruments become available
retains TUV SUD America to complete ISO 13485 and audit.
New testing to increase MammoView sterilization life.
Sales still increasing.
2013
TUV SUD America stage 1 audit completed
COMING SOON......
95% Merger/acquisition
Audit 2 results
ISO 13485
CE mark
SNDY goes international
AI
